Literature DB >> 2872071

Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions.

P Barone, T A Davis, A R Braun, T N Chase.   

Abstract

The effect of selective D-1 and D-2 dopamine receptor agonists (SKF 38393 and LY 171555, respectively) on motor function was studied in rats with unilateral, quinolinic acid-induced striatal lesions. Dose-dependent turning ipsilateral to the side of the lesion was elicited by LY 171555, but not by SKF 38393. When the drugs were given together, however, SKF 38393 was able to increase the total number (but not the duration) of turning induced by LY 171555 in a dose-dependent fashion. Furthermore, either alpha-methyl-paratyrosine pretreatment, a DA-depleting agent, or SCH 23390, a D-1 antagonist, inhibited the LY 171555-induced rotation, which would be restored by SKF 38393. These observations suggest that both the D-1 and D-2 dopamine receptor systems participate in the regulation of rotational behaviors in striatally lesioned rats with normosensitive DA receptors.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2872071     DOI： 10.1016/0014-2999(86)90694-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  26 in total

1.  Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors.

Authors:  D Eilam; H Talangbayan; G Canaran; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism.

Authors:  E P Bello; R Casas-Cordero; G L Galiñanes; E Casey; M A Belluscio; V Rodríguez; D Noaín; M G Murer; M Rubinstein
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

4.  Opposing actions of D-1 and D-2 dopamine receptor-mediated alterations of adenosine-3',5'-cyclic monophosphate (cyclic AMP) formation during the amphetamine-induced release of endogenous dopamine in vitro.

Authors:  A J Azzaro; J Liccione; J Lucci
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

5.  Postsynaptic bimodal effect of sulpiride on locomotor activity induced by pergolide in catecholamine-depleted mice.

Authors:  M Rubinstein; O Gershanik; F J Stefano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

6.  Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats.

Authors:  R Dall'Olio; O Gandolfi; A Vaccheri; P Roncada; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.

Authors:  A M Zarkovsky; K S Cereska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

8.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

9.  In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390.

Authors:  S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Behavioral effects of selective and nonselective dopamine agonists on young rats after irreversible antagonism of D1 and/or D2 receptors.

Authors:  S A McDougall; C A Crawford; A J Nonneman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.